Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 26, 2015 3:25 PM ET

Healthcare Equipment and Supplies

Company Overview of Predictive Biosciences, Inc.

Company Overview

Predictive Biosciences, Inc. develops novel molecular diagnostic cancer assays and provides urology-focused anatomic pathology laboratory products and services. It develops Clinical Intervention Determining Diagnostic and Multi-Analyte Diagnostic Readout approaches for cancer management by combining its novel clinical approaches and biomarkers. The company also offers CertNDx tests, a line of cancer assays enabling physicians to non-invasively determine the absence of cancer in patients with high negative predictive value, including CertNDx Molecular Grading Assay, a molecular diagnostic and prognostic information for bladder cancer; and CertNDx Bladder Cancer Assay, a non-invasive urine bas...

128 Spring Street

400 Level

B Annexure

Lexington, MA 02421

United States

Founded in 2006

Phone:

781-402-1780

Fax:

781-402-1785

Key Executives for Predictive Biosciences, Inc.

Co-Founder and Chairman of the Scientific Advisory Board
Co-Founder, Director and Member of the Scientific Advisory Board
Co-Founder
Chief Financial Officer
Age: 48
Chief Commercial Officer
Compensation as of Fiscal Year 2014.

Predictive Biosciences, Inc. Key Developments

Predictive Biosciences Announces Partnership with ARUP Laboratories

Predictive Biosciences, Inc. announced a partnership with ARUP Laboratories, Inc. to offer the company's molecular diagnostic bladder cancer tests to ARUP's national network of clients. Through a non-exclusive agreement, ARUP will offer Predictive's CertNDx(TM) Bladder Cancer Assays in its comprehensive test menu to hospitals, healthcare providers, academic medical centers and military and government facilities around the country. ARUP's clients will be able to order CertNDx testing, submit samples and receive all results through ARUP. Predictive Biosciences will run the diagnostic testing in its CAP and CLIA-certified laboratory. The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test to assess patients with hematuria and to monitor for bladder cancer recurrence post treatment. The test's unique approach stratifies patients based on their likelihood of bladder cancer and is highly accurate across all stages and grades of bladder cancer. CertNDx testing is also available in a tissue-based prognostic test for molecular grading that can provide a quantitative molecular assessment of tumor grade including the likelihood of disease progression.

Similar Private Companies By Industry

Company Name Region
Smart Caregiver Corporation United States
iSense Acquisition, LLC United States
DemeTech Corporation United States
Mini-Mitter Company, Inc. United States
CSF Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Predictive Biosciences, Inc., please visit www.predictivebiosci.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.